Abstract
Background
Off-label or unlicensed medicine use is very common in paediatric practice, ranging from 11 to 80 %, and is one of the predisposing factors for adverse events (23–60 %). Medicine indications are the third leading reason for doctors to perform off-label prescriptions.
Objective
The aim of our study was to determine the prevalence and nature of off-label and unlicensed medicine prescriptions in children and propose methods for risk reduction and management.
Setting
475 bed maternity-paediatric university hospital.
Method
Retrospective cross-sectional study lasting 1 day on new prescriptions issued over the previous 24 h by departments using electronic prescribing. Age and indication were compared to those in the French independent formulary Thériaque® database.
Main outcome measure
Number of off-label/unlicensed prescriptions, number of patients, proportion of off-label/unlicensed prescriptions by age group, treatment class and International Non proprietary Name (INN), using the established classification.
Results
A total of 315 prescription medicines were analysed for 120 patients, of average age 5.1 years old. For the classification of medicine utilisation, the majority of the medicines were prescribed as licensed (190/60.3 %), followed by off-label (115/36.5 %) and unlicensed (10/3.2 %) medicines. Alimentary tract, metabolic and nervous system medicines constituted the most widely prescribed ATC classes. At least 54 % of patients received an off-label/unlicensed medicine. The indications for these were mainly for off-label prescriptions (80/25.4 %) followed by medicines not evaluated for safety and regarding safety and efficacy in children (14/4.5 %). Pantoprazole was the most widely prescribed off-label INN for stress ulcer prevention (62 %). For risk reduction, we found esomeprazole being prescribed instead of pantoprazole; esomeprazole is indicated for children under a year old.
Conclusion
This study reflects one given day: 36.5 % of off-label prescriptions and 3.2 % of unlicensed prescriptions in a paediatric setting. Few risk reductions for off-label number prescriptions have been found. This work confirmed the necessity of carrying out further studies in children.
Similar content being viewed by others
References
Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatr. 2005;164(9):552–8.
Cuzzolin L, Atzei A, Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin Drug Saf. 2006;5:703–18.
Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol. 2001;52:77–83.
Ribeiro M, Jorge A, Macedo AF. Off-label drug prescribing in a Portuguese Paediatric Emergency Unit. Pharm: Int J Clin; 2012.
Horen B, Montastruc JL, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol. 2002;54:665.
European Medicines Agency EMA. ICH Topic E 11—Clinical investigation of medicinal products in the paediatric population. 2001.
Turner S, Longworth A, Nunn AJ, Choonara I. Unlicensed and off label drug use in paediatric wards: prospective study. BMJ. 1998;316:343–5.
European Medicines Agency EMA. Revised priority list for studies on off-patent paediatric medicinal products [Internet]. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/10/WC500004017.pdf.
Nguyen K-A, Claris O, Kassai B. Unlicensed and off-label drug use in a neonatal unit in France. Acta Paediatr. 2011;100:615–7.
Morales-Carpi C, Estañ L, Rubio E, Lurbe E, Morales-Olivas FJ. Drug utilization and off-label drug use among Spanish emergency room paediatric patients. Eur J Clin Pharmacol. 2010;66:315–20.
Palčevski G, Skočibušić N, Vlahović-Palčevski V. Unlicensed and off-label drug use in hospitalized children in Croatia: a cross-sectional survey. Eur J Clin Pharmacol. 2012;68:1073–7.
Nguyen K-A, Claris O, Kassai B. Unlicensed and off-label drug use in a neonatal unit in France. Acta Pediatr Oslo Nor. 1992;2011(100):615–7.
Chalumeau M, Tréluyer JM, Salanave B, Assathiany R, Chéron G, Crocheton N, et al. Off label and unlicensed drug use among French office based paediatricians. Arch Dis Child. 2000;83:502–5.
Ekins-Daukes S, Helms PJ, Taylor MW, McLay JS. Off-label prescribing to children: attitudes and experience of general practitioners. Br J Clin Pharmacol. 2005;60:145–9.
Winterfeld U, Le Heuzey M-F, Acquaviva E, Mouren M-C, Brion F, Bourdon O. Off-label use of psychotropic medications in paediatric wards: a prospective study [Utilisation hors autorisation de mise sur le marché (AMM) des psychotropes en pédiatrie: une étude prospective]. Arch Pédiatrie Organe Off Sociéte Fr Pédiatrie. 2009; 16:1252–60.
Gijsen R, Jochemsen H, van Dijk L, Caspers P. Frequency of ill-founded off-label prescribing in Dutch general practice. Pharmacoepidemiol Drug Saf. 2009;18:84–91.
Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Int Med. 2006;166:1021–6.
Walton SM, Schumock GT, Lee K-V, Alexander GC, Meltzer D, Stafford RS. Prioritizing future research on off-label prescribing: results of a quantitative evaluation. Pharmacotherapy. 2008;28:1443–52.
Acknowledgments
We wish to thank Jean-François Hartmann, Philippe Sachs, Jean-Hugues Dalle, Marc Fila, Mathie Lorrot, Estelle Litzelmann, Chrystèle Madre, Stéphane Auvin, Valérie Biran and Xavier Dode for participating in the data collection.
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
None.
Rights and permissions
About this article
Cite this article
Joret-Descout, P., Prot-Labarthe, S., Brion, F. et al. Off-label and unlicensed utilisation of medicines in a French paediatric hospital. Int J Clin Pharm 37, 1222–1227 (2015). https://doi.org/10.1007/s11096-015-0191-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-015-0191-3